SEARCH

SEARCH BY CITATION

References

  • Bosch, F., Ferrer, A., Lopez-Guillermo, A., Gine, E., Bellosillo, B., Villamor, N., Colomer, D., Cobo, F., Perales, M., Esteve, J., Altes, A., Besalduch, J., Ribera, J.M. & Montserrat, E. & For the GELCAB (Grup per l’Estudi dels Limfomes) (2002) Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. British Journal of Haematology, 119, 976984.
  • Bosch, F., Ferrer, A., Villamor, N., Gonzalez, M., Briones, J., Gonzalez-Barca, E., Abella, E., Gardella, S., Escoda, L., Perez-Ceballos, E., Peschel, C., Asensi, A., Sayas, M.J., Font, L., Altes, A., Muntanola, A., Bertazzoni, P., Rozman, M., Aymerich, M., Gine, E. & Montserrat, E. (2008) Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clinical Cancer Research, 14, 155161.
  • Bosch, F., Abrisqueta, P., Villamor, N., Terol, M.J., Gonzalez-Barca, E., Ferra, C., Gonzalez Diaz, M., Abella, E., Delgado, J., Carbonell, F., Garcia Marco, J.A., Escoda, L., Ferrer, S., Monzo, E., Gonzalez, Y., Estany, C., Jarque, I., Salamero, O., Muntanola, A. & Montserrat, E. (2009) Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. Journal of Clinical Oncology, 27, 45784584.
  • Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M.J.S., Bezares, R.F., Pettitt, A.R., Hamblin, T., Milligan, D.W., Child, J.A., Hamilton, M.S., Dearden, C.E., Smith, A.G., Bosanquet, A.G., Davis, Z., Brito-Babapulle, V., Else, M., Wade, R. & Hillmen, P. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. The Lancet, 370, 230239.
  • Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O’Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 49904997.
  • Foran, J.M., Rohatiner, A.Z.S., Cunningham, D., Popescu, R.A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P.W.M., Gisselbrecht, C., Reyes, F., Radford, J.A., Bessell, E.M., Souleau, B., Benzohra, A. & Lister, T.A. (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for Patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small b-cell lymphocytic lymphoma. Journal of Clinical Oncology, 18, 317324.
  • Goldman, A.I. & Hannan, P.J. (2001) Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm. Statistics in Medicine, 20, 15751589.
  • Hainsworth, J.D., Litchy, S., Barton, J.H., Houston, G.A., Hermann, R.C., Bradof, J.E. & Greco, F.A. (2003) Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase ii trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 21, 17461751.
  • Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, C., Seymour, J.F., Berrebi, A., Jäger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Bühler, A., Winkler, D., Zenz, T., Böttcher, S., Ritgen, M., Mendila, M., Kneba, M., Döhner, H., Stilgenbauer, S.; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label phase 3 trial. Lancet, 376, 116474.
  • Hallek, M., Cheson, B.D., Catovsky, D., Cligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R. & Kipps, T.J. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 54465456.
  • Hendry, L., Bowen, A., Matutes, E., Swansbury, J. & Catovsky, D. (2004) Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-hodgkin’s lymphoma. Leukemia and Lymphoma, 45, 945950.
  • Huhn, D., von Schilling, C., Wilhelm, M., Ho, A.D., Hallek, M., Kuse, R., Knauf, W., Riedel, U., Hinke, A., Srock, S., Serke, S., Peschel, C. & Emmerich, B. (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood, 98, 13261331.
  • Itälä, M., Geisler, C.H., Kimby, E., Juvonen, E., Tjonnfjord, G., Karlsson, K. & Remes, K. (2002) Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. European Journal of Haematology, 69, 129134.
  • Kwok, M., Rawstron, A.C., Varghese, A. & Hillmen, P. (2009) Minimal residual disease is a predictor for progression-free and overall survival in chronic lymphocytic leukemia (cll) that is independent of the type or line of therapy. (Abstract). ASH Annual Meeting Abstracts, 114, 540.
  • Machin, D., Campbell, M.J., Fayers, P.M. & Pinol, A.P.Y. (1997) Sample Size Tables for Clinical Studies, 2nd edn. Blackwell Science Ltd, Oxford.
  • McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., ce-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 28252833.
  • Moher, D., Schulz, K.F. & Altman, D.G. for the CONSORT Group (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Annals of Internal Medicine, 134, 657662.
  • Nguyen, D.T., Amess, J.A., Doughty, H., Hendry, L. & Diamond, L.W. (1999) IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin’s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. European Journal of Haematology, 62, 7682.
  • Rawstron, A.C., Kennedy, B., Evans, P.A., Davies, F.E., Richards, S.J., Haynes, A.P., Russell, N.H., Hale, G., Morgan, G.J., Jack, A.S. & Hillmen, P. (2001) Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood, 98, 2935.
  • Rawstron, A.C., Villamor, N., Ritgen, M., Bottcher, S., Ghia, P., Zehnder, J.L., Lozanski, G., Colomer, D., Moreno, C., Geuna, M., Evans, P.A.S., Natkunam, Y., Coutre, S.E., Avery, E.D., Rassenti, L.Z., Kipps, T.J., Caligaris-Cappio, F., Kneba, M., Byrd, J.C., Hallek, M.J., Montserrat, E. & Hillmen, P. (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia, 21, 956964.
  • Robak, T., Moiseev, S.I., Dmoszynska, A., Solal-Celigny, P., Warzocha, K., Loscertales, J., Catalano, J., Afanasiev, B.V., Larratt, L., Geisler, C., Montillo, M., Ganly, P., Dartigeas, C., Rosta, A., Janssens, A., Mendila, M., Maurer, J. & Wenger, M.K. (2008) Rituximab, fludarabine, and cyclophosphamide (r-fc) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (cll) compared with fc alone: final results from the international randomized phase iii reach trial. (Abstract). Blood (ASH Annual Meeting Abstracts), 112, lba1.
  • Van Glabbeke, M., Steward, W. & Armand, J.P. (2002) Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies? European Journal of Cancer, 38, 635638.
  • Wierda, W., O’Brien, S., Wen, S., Faderl, S., Garcia-Manero, G., Thomas, D., Do, K.A., Cortes, J., Koller, C., Beran, M., Ferrajoli, A., Giles, F., Lerner, S., Albitar, M., Kantarjian, H. & Keating, M. (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 40704078.
  • Wilder, D.D., Ogden, J.L. & Jain, V.K. (2002) Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin’s lymphoma. Clinical Lymphoma, 2, 229237.
  • Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V. & Engert, A. (1999) Cytokine-release syndrome in patients with b-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood, 94, 22172224.
  • Zinzani, P.L., Magagnoli, M., Moretti, L., Battista, R., Ronconi, F., De Renzo, A., Zaccaria, A., Gentilini, P., Guardigni, L., Gherlinzoni, F., Cellini, C., Fattori, P.P., Bendandi, M., Bocchia, M., Aitini, E. & Tura, S. (1999) Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients. Haematologica, 84, 10021006.